United States Biopharmaceutical Fermentation Systems Market 2025 | Growth Drivers, Market Forecast, Competitive Landscape & Business Opportunities

Market Size and Growth

The global biopharmaceutical fermentation systems market is estimated to reach at a high CAGR of 5,9% during the forecast period 2024-2031.

Key Development:

United States: Recent Biopharmaceutical Fermentation Developments

✅ In September 2025, the U.S. biopharmaceutical fermentation systems market was projected to reach $26.6 billion, reflecting an 8.1% growth from 2024. This surge is attributed to increased demand for biologics and advancements in manufacturing technologies.

✅ In August 2025, ProBio launched an end-to-end adeno-associated virus (AAV) production facility in New Jersey. The site supports scalable manufacturing with batch sizes ranging from 50 L to 200 L, accommodating both early and late-phase clinical needs.

✅ In June 2025, Ecolab Life Sciences introduced the Purolite AP+50 affinity chromatography resin at the BIO International Convention in Boston. This innovation enhances antibody manufacturing processes by optimizing operations.

Japan: Recent Biopharmaceutical Fermentation Developments

✅ In September 2025, Japanese biotech firm Fermenta secured ¥2 billion in Series A funding to produce rare natural compounds through fermentation. A pilot plant is scheduled for completion in 2026.

✅ In August 2025, Japan's AMED announced a "Double Match Up" grant program for biopharma startups. The initiative offers up to ¥6.7 billion in grants, matching venture capital investments to support pharmaceutical development pipelines.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/biopharmaceutical-fermentation-systems-market?sb

Recent Mergers and Acquisitions :

United States: Recent M&A in Biopharmaceutical Fermentation

✅ In August 2025, Roche announced the acquisition of 89bio for $3.5 billion. This strategic move aims to bolster Roche's pipeline in metabolic diseases, particularly focusing on 89bio's lead asset, pegozafermin, currently in clinical trials for treating obesity-related conditions.

✅ In January 2025, Roche completed its acquisition of Poseida Therapeutics for approximately $1.5 billion. Poseida specializes in allogeneic CAR-T cell therapies, enhancing Roche's capabilities in advanced cell therapy solutions.

✅ In December 2022, MilliporeSigma, a U.S.-based life sciences company, acquired Erbi Biosystems Inc. This acquisition integrated Erbi's Breez micro-bioreactor platform technology, facilitating scalable cell-based perfusion bioreactor processes and promoting innovation in continuous bioprocessing.

Key Players:

=> Corning, Inc., Thermo Fisher Scientific Inc., Danaher Corporation, Sartorius StedimBiotech, Merck KGaA (Merck Millipore), Eppendorf AG, 3M Company., Nova Biomedicals, Lonza, and Repligen Corporation.
Growth Forecast Projected:

The Global Biopharmaceutical fermentation systems Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Biopharmaceutical fermentation systems Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=biopharmaceutical-fermentation-systems-market

Key Segments:

➥ By Product: Upstream Products, Downstream Products

➥ By Application: Monoclonal Antibodies, Recombinant Proteins, Antibiotics, Probiotics

➥ By End-User: Biopharmaceutical Companies, Contract Manufacturing Organizations, Contract Research Organizations, Academic Research Institutes, Food Industry

Regional Analysis for Biopharmaceutical fermentation systems Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Biopharmaceutical fermentation systems producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Biopharmaceutical fermentation systems revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/biopharmaceutical-fermentation-systems-market?sb

FAQ

Q: What is the growth rate of the Biopharmaceutical fermentation systems Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 5,9% during the forecast period from 2024 to 2031.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.